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We present a case report of total knee arthroplasty complicated by spasticity and contractures in a patient
with multiple sclerosis (MS). Four previous case reports in the literature describe adverse outcomes
after total knee arthroplasty in persons with MS secondary to severe spasticity. Preoperative, intra-
operative, and postoperative considerations for persons with MS, which may help to improve functional
outcomes, are discussed. Prospective research is needed among persons with MS to help determine the
timing and selection of persons for arthroplasty and to minimize complications related to spasticity.
© 2016 The Authors. Published by Elsevier Inc. on behalf of The American Association of Hip and Knee
Surgeons. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).Introduction
Multiple sclerosis (MS) is a chronic, degenerative inﬂammatory
disease of the central nervous system. It is estimated that 2.3
million people worldwide have MS with the highest prevalence
rates reported in North America and Europe [1]. The etiology of MS
is not fully understood, involving autoimmune mechanisms in
genetically susceptible individuals [2]. The prevalence of arthritic
comorbidity among persons with MS is still an evolving area of
research and is estimated to be in the range of 16%-26% [3,4].
Although total knee arthroplasty (TKA) may lead to enhanced
function for selected persons with MS, to date, the literature
highlights only case reports with adverse outcomes and limited
follow-up. Here, we present the 2-year follow up of a 75-year-old
woman with primary progressive MS who received a right TKA for
osteoarthritis 18 years after the initial onset of MS symptoms.
Case history
Informed consent was obtained for the case report. MS onset
was at age 57 involving nonremitting right hand weakness andd any potential or pertinent
conﬂict with this work. For
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Inc. on behalf of The American Asso
c-nd/4.0/).numbness followed by progressive symptoms of right spastic toe
ﬂexor posturing and foot drop. These symptoms occurred over the
course of 12 months. She fulﬁlled diagnostic criteria for primary
progressive MS [5] with periventricular brain T2 lesions onmagnetic
resonance imaging, positive oligoclonal bands in the cerebrospinal
ﬂuid, and disease progression for 1 year. She experienced a gradual
decline in her mobility in the absence of relapsing symptoms over
time. Fourteen years after MS onset, she progressed to needing a gait
aid (cane or walker) intermittently for community mobility.
Fifteen years after MS onset, the patient experienced progressive
right knee pain consistent with osteoarthritis. Over the course of 3
years, she failed conservative measures for pain relief, including
intra-articular knee corticosteroid injections, acetaminophen and
naproxen. She remained ambulatorywith a single straight cane for at
least 100 m but began to use a wheelchair largely for community
mobility. The patient experienced a fall, which did not result in
serious injury but did provoke a fear of future falls. The surgeon’s
notes detail the patient experiencing pain with weight-bearing
during transfers. The patient elected to proceed with knee arthro-
plasty. Preoperative radiographs showed severe lateral and mild-to-
moderate medial osteoarthritis of the right knee (Fig. 1).
Medical history included thyroid disease and depression. Pre-
operative lower extremity strength was grade 3 bilaterally for
hip ﬂexion and grade 4 for all other muscle groups. Tonewas mildly
increased in both lower limbs with preserved full range of motion.
There was nonsustained clonus at both ankles. Preoperative med-
ications were baclofen 10 mg/day and oxybutynin 5 mg/day.ciation of Hip and Knee Surgeons. This is an open access article under the CC BY-NC-
Figure 1. Preoperative (a) anteroposterior, (b) lateral, and (c) Merchant radiographs.
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general anesthetic without administration of nerve blocks.
Cefazolin was provided preoperatively. A standard midline
approach with a medial parapatellar arthrotomy was used. Signif-
icant lateral compartment arthritis and contracture were evident
during the surgical procedure. Components were sized, trialed, and
cemented into place with Palacos RþG cement (Zimmer, Warsaw,
IN). The components were from the Zimmer NexGen LPS total knee
system (Zimmer, Warsaw, IN). These components provided good
range of motion and soft tissue balancing at the conclusion of the
surgery. Aside from the muscle contracture, no other problems
were encountered intraoperatively. The bone and soft tissue quality
was adequate. The articular capsule was of good quality and there
was not any scar tissue noted. The patella was inspected intra-
operatively. The articular cartilage was of good quality, and it
tracked well after implantation of the components; thus, the de-
cisionwas made to not resurface the patella. A tourniquet was used
and no excessive bleeding was encountered. Excellent hemostasis
was achieved at the end of the case.
Postoperatively, the patient developed a signiﬁcant increase in
her lower extremity spasticity and related pain. Postoperative
imaging was negative for deep vein thrombosis, joint effusion, or
other complications (Fig. 2). She received 4 doses of intravenous
morphine 2-3 mg in the recovery room with gabapentin 200 mg
followed by scheduled acetaminophen 650 mg every 4 hours,
gabapentin 100 mg tid, celecoxib 100mg bid, and sustained release
hydromorphone 3 mg with senna bid postoperatively. Immediate
release hydromorphone 1-4 mg was ordered prn and rarely used.
Scheduled sustained release hydromorphone was discontinued on
postoperative day 7. She assumed a crouch gait on trial of weight
bearing.
On postoperative day 19, the patient was transferred to inpa-
tient rehabilitation after developing severe lower extremity tone
with bilateral knee contractures. She received range of motion
exercises and gait training twice daily. Thirty days postoperative,
botulinum (300 IU) was administered into the right medial and
lateral hamstrings. She was discharged to the community 75 dayspostoperatively after achieving an independent gait with a
4-wheeled walker for 40 m and near-full passive range of motion
of 15 to 120 of ﬂexion at both knees. Discharge medications
were baclofen 10 mg qam and 20 mg qhs. Higher daytime doses of
antispasticity medications were not tolerated because of a side
effect of generalized weakness.
After discharge to the community, despite reported compliance
with a home exercise program, the right knee ﬂexion contracture
worsened to 35. She received repeat botulinum injections of 300 IU
divided between the right medial hamstrings and hip adductors at 4
and 7 months postoperatively with minimal improvement. Ambu-
lation status continued to decline over the next year such that
walking became limited to 5 m with a walker and an assistant. The
patient expressed frustration as she had hoped to regain ambulatory
status without aids after the arthroplasty. She began more intense
outpatient physiotherapies involving use of a standing frame,
assisted platform walking, and range-of-motion exercises. She also
accessed services through a community exercise group, which pro-
vided specialized support for persons with disability. At 24 months
postoperatively, she had improved her walking distance back to
short household distances independently with a 4-wheeled walker.
Discussion
In our case, sustained spasticity postoperatively was largely
refractory to medical management. Spasticity is part of the upper
motor neuron syndrome and is common among persons with MS
[6]. Previous MS case reports have also described severe spasticity
resulting in adverse short-term outcomes after TKA (Table 1). In our
case, at 2 years after arthroplasty and 20 years after the onset of
progressive MS, the patient had maintained her ambulatory status
with a 4-wheeled walker for household distances. The patient
however was not satisﬁed with her protracted course of rehabili-
tation or her functional outcome. Finding the optimal timing of
knee arthroplasty for persons with MS and identifying additional
factors in preoperative, intraoperative, and postoperative TKA care
among persons with MS may help to optimize future outcomes.
Figure 2. Postoperative (a) anteroposterior, (b) lateral, and (c) Merchant radiographs.
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disability progression, and MS-speciﬁc treatment considerations
The majority of persons with MS begin with a relapsing-
remitting MS course (RRMS) where new or worsening neurologic
symptoms appear and then remit or improvewithin days, weeks, or
several months [10]. As many as 50% presenting with RRMS may
remain ambulatory without the use of cane 25 years after MS onset
[11], therefore, the majority of persons with RRMS may expect to
remain independently ambulatory for a signiﬁcant portion of their
adult life (Table 2). However, over time, most persons with RRMS
experience a transition to a secondary progressive MS courseTable 1
Adverse short-term outcomes after TKA.
Case Demographic Years diagnosed
with MS
Complications Po
1 [7] 59-year-old woman 10 Recurrent knee dislocations M
kn
2 [8] 70-year-old man 46 Hamstring spasticity Kn
w
3 [8] 74-year-old man ~50 Hamstring spasticity and
dislocation of rotating
tibial insert
Do
4 [9] 64-year-old woman 30 Hamstring spasticity and
posterior knee dislocation
1 month postoperatively
Exwhere disability progression continues largely in the absence of
ongoing relapse. Approximately 10% of persons with MS present at
onset with a primary progressive course, experiencing disability
progression over time in the absence of relapses. A primary pro-
gressive MS course at onset carries a worse prognosis for earlier
disability progression compared to RRMS. However, as more
advanced disability milestones are achieved, rates of further
disability progression become more comparable (Table 2).
Although MS is an unpredictable disease, knowledge of the
patient’s individual MS disease course and mobility decline over
time may help to inform the selection, timing, and expectations for
TKA. The goals of TKAmay differ, depending on the stage and rate ofstoperative aid Postoperative
antispasmodic
Sequelae
obile-bearing
ee prostheses
Tizanidine Presented to the emergency department
followed with revision procedure
(replacement with a thicker polyethylene
insert). Loss of extension of the knee and
residual hamstring spasms. A second
nocturnal spasm resulted in a second
dislocation with open reduction followed
by cylinder cast.
ee brace and
alking stick
Baclofen Progressive anterior knee pain 2 years
with elective surgical release of gracilis
and later, biceps femoris tendon.
Ultimately pain free with 4/5 quadraceps
power, mobilizing with knee brace and
walking stick
njoy brace Baclofen Open reduction of component was required
and hamstrings released. Unhappy with
result and being treated for depression.
tension splint Baclofen Closed reduction of dislocated prosthesis
unsuccessful, therefore subsequent revision
of TKA required with prophylactic
botulinum injections to right hamstring
Table 2
Disability progressiona and survival in relapsing-remitting MS vs primary progres-
sive MS.
Outcomes Relapsing-remitting MS Primary
progressive MS
Estimated median time (y)
from MS onset to required
cane use [12-14]
23-30 7-13
Estimated median time (y)
from cane use to wheelchair
level mobility [12]
3 4
Estimated median age at MS
onset of ﬁrst symptoms [13]
29 40
Estimated median survival (y)
from MS onset [15,16]
43-50 26-33
a Although the median reported time for disability milestones and survival may
be helpful in understanding outcomes, it is important to remember that MS is a
highly variable disease.
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gressive MS and began using mobility devices several years before
her TKA and before clearly documented knee pain. Given our
patient’s scenario, continued use of mobility aids would be antici-
pated after TKA despite the fact that our patient had greater
expectations for improvement. Arthroplasty may have helped to
prolong her independence with transfers and walking function
with aids by alleviating pain, allowing for longer term continued
activity and preventing deconditioning weakness.
In the future, more objective documentation of mobility decline
over time before TKA may help to better inform the prognosis and
expectations after arthroplasty. Objective assessment of mobility
impairment may be achieved with the Timed 25-Foot Walk test
[17,18] performed serially over time. A 20% change in the patient’s
fastest walking speed is considered clinically relevant. A careful
clinical history may differentiate a decline in mobility related to MS
symptoms from restrictions secondary to arthritic comorbidity.
In addition to the rate of mobility decline, relapse history may
impact TKA decision-making for those patients with RRMS. Pulse
steroids, which may be used in the management of severe MS
relapses, could impact bone health and risk of joint infection and
delay wound healing. A period of severe fatigue and deconditioning
may also follow a relapse. Most patients with recurring relapses
would be considered for MS disease-modifying treatment or for a
switch in their treatment regime if already on treatment. True MS
relapses are not to be confused with pseudorelapses where a
temporary worsening of previous or existing neurologic symptoms
occurs under the inﬂuence of a stressor, including the stress of
surgery. There is currently little evidence that surgery increases the
risk of true MS relapses. A detailed preoperative and postoperative
neurologic history and examination may help to differentiate true
relapses from pseudorelapses after surgery.
Disease-modifying therapies for patients with RRMS have
reduced the relative risk of true relapses by as much as 30%-70% in
clinical trials. The ﬁrst-line injectable disease-modifying therapies
(glatiramer acetate and interferons) may be safely continued
through the perioperative period as long-term data do not support
an increased risk of infectionwith their use. Long-term data on risk
of infection and practice patterns for the newer oral ﬁrst-line
therapies (dimethyl fumarate and teriﬂunomide) through the
perioperative period are not yet available. For treatments largely
considered second line (natalizumab, ﬁngolimod, and alemtuzu-
mab), the risk of infection is higher than that with the ﬁrst-line
treatments. While no guidelines exist in MS for stopping MS
treatment before surgery, second-line treatments as well as newer
and emerging ﬁrst-line treatments have shownmore potent effectson the immune system. The consequences of stopping therapies
could result in rebound MS disease activity for some patients. An
individualized assessment of risk, disability progression, relapses,
and response to treatment history may help to inform the optimal
timing and selection of appropriate patients for TKA.Preoperative planning once a decision has been made for TKA
Milder ﬂuctuating or more severe paroxysmal MS symptoms
may occur independent of MS relapses and should be optimally
managed before surgery, especially spasticity. In their report of
2 cases with refractory postoperative spasticity, Shannon et al. [8]
proposed that a preoperative increase in oral antispasticity medi-
cation might reduce the risk for severe postoperative spasticity.
Although this may be a reasonable approach for selected patients,
intolerable side effects often do not allow sufﬁcient dose titration to
control the spasticity. This was the case with our patient. Poor
patient satisfaction with available antispasticity pharmacological
options is common in MS [19].
Because spasticity may be worsened under any stressors,
screening and treating stressors may have a marked impact on the
spasticity. Some treatable common stressors include urinary tract
infection (UTI), urinary retention, constipation, uncontrolled pain,
and severe anxiety. The usual symptoms of UTI may not be readily
apparent in persons with MS. Prophylactic treatment for UTI does
not decrease the risk of joint infection in general populations [20],
but routine screening or prophylactic treatment of UTI in MS
patients preoperatively may warrant consideration to reduce
postoperative complications related to both spasticity and infection.
The focal administration of high-dose botulinum into the hip
adductors has been shown to be effective in reducing lower
extremity spasticity in MS [21], although its effect on function is
less clear. Botulinum could be considered preoperatively in high-
risk patients with increased baseline lower extremity spasticity.
Appropriate planning would be required to target speciﬁc muscles.
Peak effects from botulinum occur within weeks [22]. Approxi-
mately 1/3 of patients may experience temporary focal weakness
which may necessitate additional measures to prevent falls [23].
A preoperative approach with botulinum warrants further study,
especially given the limited efﬁcacy and tolerability of oral phar-
macotherapy options [24].
Intrathecal baclofen is another option highly effective in the
treatment of spasticity and underused in MS care [25]. There may
be a role for intrathecal baclofen in ambulatory patients with severe
baseline spasticity. The intrathecal administration offers ﬁne dose
titration without systemic side effects [26]. However, consultation
and coordination with specialized services would be required.
A preoperative rehabilitation conditioning programmay help to
reduce spasticity and offer other advantages. Although there is
low-level evidence that physical activity and other modality
interventions reduce spasticity [27], patients may experience
improved MS symptoms and improved physical functioning with
physical activity programs [28]. Cognitive impairment, mood dis-
order, and potential barriers for compliance with a programmay be
overcome with additional supports in place.Intraoperative care and postoperative planning
Our patient had signiﬁcant lateral compartment contracture at
the time of her surgery. Because the future stability of the knee is
also a concern, it would seem reasonable to avoid tendon releases if
possible. In our patient, sufﬁcient range of motion was achieved
without tendon releases; however, she later developed severe
contractures. Possibly targeting the lateral hamstrings with
KEY POINTS
 Although MS is a progressive disease of the central nervous
system, patients may maintain ambulatory function for a
signiﬁcant duration of their adult lives, and therefore, optimal
management of osteoarthritis limiting function is warranted.
 Spasticity in persons with multiple sclerosis may lead to
complications after TKA including late contractures and
dislocations.
 More work is needed to determine how to optimally prevent
complications related to severe spasticity after TKA. Early and
prolonged intensiﬁed rehabilitation programs, more aggres-
sive use of early botulinum, and intrathecal baclofen may
warrant further consideration.
 Although MS is a highly variable and unpredictable disease,
knowledge of the patient’s individual MS disease course and
mobility decline over time may help to better inform the se-
lection and timing for TKA.
 Efforts should be made to align the expectations of people
with MS undergoing arthroplasty with the possible and likely
outcomes related to their individual situation.
K.E. Hughes et al. / Arthroplasty Today 2 (2016) 117e122 121botulinum intraoperatively or earlier in the postoperative period
may have prevented the contracture formation.
To ensure stability of the TKA, Rao et al. [7] recommended in
their case report a ﬁxed-bearing posterior-stabilized prosthesis.
A more constrained prosthesis in patients with severe spasticity
may reduce the risk of dislocation. Although this was not needed for
our patient, a previous dislocation was reported by Bron et al. [9].
Minimizing postoperative complications and maximizing pain
control using a multi-modal approach may reduce postoperative
spasticity. Shannon et al. [8] proposed a prolonged period of
regional anesthesia postoperatively. In a large Italian study of
childbirth among women with MS, epidural anesthetic was not
associated with an increased risk of subsequent relapses or
disability progression [29]. If no other contraindications exist,
patients should be offered spinal analgesia over general anesthetic.
Continuous peripheral nerve blocks, perineural local anesthetic
infusion, systemic opioid and nonopioid pain medications
(including medications for neuropathic pain) may all be considered
in combination for early and aggressive pain control. A regular
comprehensive bowel care regime is also important because
patients with MS are prone to neurogenic bowel [30].
While the recommended duration of treatment for thrombo-
embolism prophylaxis is 10-35 days for general TKA populations
[31,32], as patients with MS may be slower to mobilize, we suggest
that longer durations be considered. Although continuous passive
motion devices may not be routine care in general orthopaedic TKA
practices [33], these devices may have a role for patients withMS at
higher risk for complications related to immobility.
Given the barriers to physical activity that persons with MS
experience [34] and the progressive nature of the disease, persons
with MS may beneﬁt from prolonged and individualized support
from physical therapists to achieve and maintain their maximum
functional potential after TKA. While there is no evidence that
extended outpatient programs supported by a physical therapist
improve long-term outcomes in the general practice of TKA [35],
this may not be the case for persons with MS. Our patient experi-
enced a functional decline and increase in her knee contracture
after discharge from inpatient rehabilitation. This occurred despite
reported compliance with a home program and limited outpatient
physical therapy follow-up. She improved back to her baseline
coincident with intensiﬁed outpatient therapies achieved through
a combination of specialized community activity groups for persons
with neurologic disability and more one-on-one outpatient phys-
ical therapy. Persons with other neurologic disability discharged
from structured inpatient rehabilitation programs experience
deconditioning and functional decline after discharge to the com-
munity [36]. There may be a case for more routine prolonged and
professionally supported rehabilitation care for persons with MS
undergoing TKA.Current controversies and future considerations
The optimal patient selection criteria and timing of TKA for
persons with MS remains unclear. Spasticity appears to be
a signiﬁcant complicating factor and optimal management is
challenging. We have proposed some of the factors that might
assist with decision-making and some considerations regarding
spasticity management. Aggressive postoperative pain control;
posterior-stabilized prostheses; early consideration for botulinum
treatment; and prolonged, intensiﬁed rehabilitation services may
help to mitigate complications related to spasticity. Oral pharma-
cotherapy may have limited efﬁcacy and tolerability in the man-
agement of severe spasticity in MS, and new approaches are
needed. In the future, monitoring of both short-term and long-termoutcomes, including patient-reported outcomes, after TKA in MS
could help to guide practice.Summary
The person’s individual disease course, their treatment history,
the natural history of MS, and whether the goals associated with
TKA may be reasonably achieved warrant consideration when
planning TKA for persons with MS. Severe spasticity refractory to
medical management is reported after TKA and may result in
complications. Our patient with progressive MS undergoing TKA
maintained ambulatory status with a walker despite initial chal-
lenges with severe spasticity. However, she was not satisﬁed, as she
did not achieve her goal of walking without aids. Monitoring future
care practices and outcomes related toTKA inMSmay help to guide
optimal management.Acknowledgments
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